X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-15 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale+OE | $92.38 | -7,947 | 31,771 | -20% | -$734,145 | |||||
| DM | 2026-09-11 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale+OE | $92.43 | -10,019 | 14,752 | -40% | -$926,010 | |||||
2026-09-15 | ORKA | Oruka Therapeutics, Inc. | Klein Lawrence Otto | CEO | S - Sale | $95.71 | -2,452 | 923,128 | 0% | -$234,681 | ||||||
2026-09-15 | ORKA | Oruka Therapeutics, Inc. | Quinlan Paul T | GC | S - Sale | $95.71 | -1,039 | 29,995 | -3% | -$99,443 | ||||||
2026-09-15 | ORKA | Oruka Therapeutics, Inc. | Sandler Laura Lee | COO | S - Sale | $95.71 | -906 | 235,478 | 0% | -$86,713 | ||||||
2026-09-15 | RARE | Ultragenyx Pharmaceutical Inc. | Huizenga Theodore Alan | SVP, Chief Accounting Officer | S - Sale | $13.57 | -1,283 | 67,863 | -2% | -$17,410 | ||||||
2026-09-15 | CYTK | Cytokinetics Inc | Landry Robert E | Dir | S - Sale | $72.13 | -1,000 | 8,184 | -11% | -$72,130 | ||||||
| DM | 2026-09-14 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $69.62 | -105,426 | 282,710 | -27% | -$7,340,010 | |||||
2026-09-14 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Ben Yong | Dir | S - Sale | $7.84 | -2,000 | 9,383 | -18% | -$15,683 | ||||||
| D | 2026-09-14 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $504.12 | -9,500 | 668,728 | -1% | -$4,789,152 | |||||
| D | 2026-09-14 | UTHR | United Therapeutics Corp | Mesa Nilda | Dir | S - Sale+OE | $505.87 | -228 | 5,580 | -4% | -$115,338 | |||||
| D | 2026-09-11 | IMNM | Immunome Inc. | Higgins Jack | Chief Scientific Officer | S - Sale+OE | $25.32 | -13,200 | 59,250 | -18% | -$334,224 | |||||
| D | 2026-09-11 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale+OE | $70.11 | -27,136 | 644,523 | -4% | -$1,902,505 | |||||
| DM | 2026-09-11 | LQDA | Liquidia Corp | Singh Raman | Dir | S - Sale+OE | $67.43 | -17,492 | 44,637 | -28% | -$1,179,453 | |||||
2026-09-14 | NAMS | Newamsterdam Pharma Co N.V. | Davidson Michael H. | CEO | P - Purchase | $22.65 | +10,000 | 1,078,638 | +1% | +$226,500 | ||||||
| M | 2026-09-11 | KRRO | Korro Bio, Inc. | Formela Jean Francois | Dir | S - Sale | $14.09 | -48,690 | 132,650 | -27% | -$686,177 | |||||
2026-09-11 | ISCO | International Stem Cell Corp | Maier Paul V | Dir | S - Sale | $0.32 | -32,802 | 0 | -100% | -$10,497 | ||||||
| D | 2026-09-14 | MIRM | Mirum Pharmaceuticals, Inc. | Bjerkholt Eric | CFO | S - Sale+OE | $98.37 | -9,943 | 44,745 | -18% | -$978,093 | |||||
| D | 2026-09-11 | PHVS | Pharvaris N.V. | Lu Peng | Pres | S - Sale+OE | $40.13 | -15,000 | 64,953 | -19% | -$601,947 | |||||
2026-09-14 | PHVS | Pharvaris N.V. | Modig Berndt | CEO | S - Sale | $39.40 | -2,291 | 1,078,334 | 0% | -$90,276 | ||||||
2026-09-14 | MAIA | Maia Biotechnology, Inc. | Vitoc Vlad | CEO, 10% | P - Purchase | $1.37 | +73,000 | 1,259,221 | +6% | +$100,010 | ||||||
2026-09-11 | ANIP | Ani Pharmaceuticals Inc | Thoma Jeanne | Dir | S - Sale | $71.53 | -1,000 | 26,762 | -4% | -$71,530 | ||||||
2026-09-14 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $70.79 | -500 | 73,924 | -1% | -$35,395 | ||||||
2026-09-10 | MNKD | Mannkind Corp | Binder Steven B. | Dir | S - Sale | $3.81 | -33,558 | 752,309 | -4% | -$127,856 | ||||||
| D | 2026-09-14 | RYTM | Rhythm Pharmaceuticals, Inc. | Meeker David P | Pres, CEO | S - Sale+OE | $102.67 | -50,000 | 239,258 | -17% | -$5,133,442 | |||||
2026-09-07 | TLX | Telix Pharmaceuticals Ltd | Smith Darren Charlton | Group CFO | P - Purchase | $9.66 | +2,071 | 13,992 | +17% | +$19,998 | ||||||
| M | 2026-09-11 | LFVN | Lifevantage Corp | Cunningham Kristen | Chief Sales Officer | S - Sale | $6.18 | -9,001 | 120,162 | -7% | -$55,649 | |||||
2026-09-10 | JAZZ | Jazz Pharmaceuticals Plc | Patil Neena M | EVP, GC | S - Sale | $240.94 | -1,200 | 47,671 | -2% | -$289,128 | ||||||
| M | 2026-09-10 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $66.39 | +3,124 | 555,000 | +1% | +$207,399 | |||||
2026-09-10 | TGTX | Tg Therapeutics, Inc. | Charney Laurence N | Dir | S - Sale | $54.96 | -5,000 | 168,640 | -3% | -$274,800 | ||||||
2026-09-10 | LGND | Ligand Pharmaceuticals Inc | Zimmermann Martine | Dir | S - Sale | $285.00 | -1,200 | 3,897 | -24% | -$342,000 | ||||||
| D | 2026-09-11 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $500.82 | -9,500 | 668,728 | -1% | -$4,757,773 | |||||
2026-09-11 | KRRO | Korro Bio, Inc. | Dolan Oliver | SVP, Finance | S - Sale | $13.72 | -5 | 16,241 | 0% | -$69 | ||||||
2026-09-10 | AMLX | Amylyx Pharmaceuticals, Inc. | Bedrosian Camille L | Chief Medical Officer | S - Sale | $32.40 | -10,028 | 278,064 | -3% | -$324,868 | ||||||
2026-09-10 | AMLX | Amylyx Pharmaceuticals, Inc. | Frates James M | CFO | S - Sale | $32.36 | -10,810 | 400,156 | -3% | -$349,821 | ||||||
2026-09-10 | AMLX | Amylyx Pharmaceuticals, Inc. | Mazzariello Gina | GC | S - Sale | $32.46 | -9,536 | 190,838 | -5% | -$309,506 | ||||||
2026-09-10 | AMLX | Amylyx Pharmaceuticals, Inc. | Klee Justin B. | Co-CEO | S - Sale | $32.18 | -30,464 | 3,613,056 | -1% | -$980,263 | ||||||
2026-09-10 | AMLX | Amylyx Pharmaceuticals, Inc. | Cohen Joshua B | Co-CEO | S - Sale | $32.19 | -30,464 | 3,613,123 | -1% | -$980,504 | ||||||
| D | 2026-09-10 | PHVS | Pharvaris N.V. | Lesage Anne | Chief Early Development | S - Sale+OE | $38.30 | -30,000 | 56,450 | -35% | -$1,149,084 | |||||
2026-09-10 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $2.75 | +3,000 | 665,000 | 0% | +$8,250 | ||||||
2026-09-10 | ANIX | Anixa Biosciences Inc | Titterton Lewis H Jr | Dir | P - Purchase | $2.73 | +10,000 | 996,967 | +1% | +$27,300 | ||||||
2026-09-10 | MAIA | Maia Biotechnology, Inc. | Guerrero Ramiro | Dir | P - Purchase | $1.32 | +37,595 | 773,296 | +5% | +$49,516 | ||||||
2026-09-11 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | CEO, Pres, 10% | P - Purchase | $3.67 | +37,000 | 7,653,140 | 0% | +$135,620 | ||||||
| M | 2026-09-10 | AARD | Aardvark Therapeutics, Inc. | Sun Nelson | See Remarks | S - Sale | $5.15 | -76,754 | 35,475 | -68% | -$394,957 | |||||
2026-09-09 | ANTX | An2 Therapeutics, Inc. | Readnour Robin Shane | Dir | S - Sale | $6.02 | -1,108 | 633,842 | 0% | -$6,675 | ||||||
2026-09-11 | CYTK | Cytokinetics Inc | Landry Robert E | Dir | S - Sale | $74.66 | -1,000 | 9,184 | -10% | -$74,660 | ||||||
| M | 2026-09-09 | PTCT | Ptc Therapeutics, Inc. | Schmertzler Michael | Dir | S - Sale | $67.59 | -20,000 | 1,316,594 | -1% | -$1,351,803 | |||||
| M | 2026-09-09 | MDGL | Madrigal Pharmaceuticals, Inc. | Sibold William John | Pres, CEO | S - Sale | $538.65 | -11,583 | 197,746 | -6% | -$6,239,198 | |||||
| D | 2026-09-10 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $502.35 | -9,500 | 668,728 | -1% | -$4,772,295 | |||||
2026-09-09 | NBP | Novabridge Biosciences | Cao Sean Wuxiong | Chief Bus. Development Officer | S - Sale | $0.74 | -107,978 | 266,467 | -29% | -$79,904 | ||||||
2026-09-09 | TYRA | Tyra Biosciences, Inc. | Verjee Rehan | Dir | P - Purchase | $20.58 | +972 | 972 | New | +$20,000 | ||||||
2026-09-10 | AUPH | Aurinia Pharmaceuticals Inc. | Robertson Stephen P. | GC | S - Sale | $15.95 | -11,939 | 588,848 | -2% | -$190,427 | ||||||
| D | 2026-09-10 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | S - Sale+OE | $17.62 | -10,185 | 39,900 | -20% | -$179,457 | |||||
2026-08-08 | AZN | Astrazeneca Plc | Sharma Mani | See Remarks | P - Purchase | $160.57 | +20 | 19,289 | 0% | +$3,249 | ||||||
| D | 2026-09-10 | TVTX | Travere Therapeutics, Inc. | Meckler Jeffrey A | Dir | S - Sale+OE | $67.31 | -20,000 | 91,500 | -18% | -$1,346,106 | |||||
2026-09-09 | INSM | Insmed Inc | Brennan David R | Dir | S - Sale | $124.00 | -25,000 | 99,238 | -20% | -$3,100,000 | ||||||
| D | 2026-09-09 | PHVS | Pharvaris N.V. | Glassman Robert | Dir | S - Sale+OE | $37.55 | -8,000 | 10,500 | -43% | -$300,396 | |||||
| M | 2026-09-07 | KMDA | Kamada Ltd | Tsur David | Dir | S - Sale | $8.26 | -177,173 | 430,756 | -29% | -$1,463,734 | |||||
| D | 2026-09-09 | AQST | Aquestive Therapeutics, Inc. | Korczynski Sherry | Chief Commercial Officer | S - Sale+OE | $5.22 | -8,750 | 235,689 | -4% | -$45,675 | |||||
2026-09-08 | CYBN | Cybin Inc. | Glavine Paul | Chief Growth Officer | P - Purchase | $12.47 | +100,000 | 4,502,193 | +2% | +$1,247,190 | ||||||
2026-09-08 | CYBN | Cybin Inc. | Glavine Paul | Chief Growth Officer | P - Purchase | $12.47 | +100,000 | 4,502,193 | +2% | +$1,247,190 | ||||||
2026-09-08 | CYBN | Cybin Inc. | So Eric H. L. | Exec Chair | P - Purchase | $12.39 | +100,000 | 4,518,630 | +2% | +$1,238,670 | ||||||
2026-09-10 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $2.76 | +5,000 | 662,000 | +1% | +$13,800 | ||||||
| M | 2026-09-09 | RLMD | Relmada Therapeutics, Inc. | Shenouda Maged | CFO | P - Purchase | $4.22 | +200,000 | 1,000,000 | +25% | +$843,990 | |||||
| M | 2026-09-09 | RLMD | Relmada Therapeutics, Inc. | Traversa Sergio | CEO | P - Purchase | $4.14 | +200,000 | 1,500,000 | +15% | +$828,000 | |||||
| DM | 2026-09-08 | PTGX | Protagonist Therapeutics, Inc | Patel Dinesh V Ph D | Pres, CEO | S - Sale+OE | $145.93 | -125,000 | 522,968 | -19% | -$18,240,568 | |||||
| D | 2026-09-08 | ROIV | Roivant Sciences Ltd. | Fitzgerald Meghan | Dir | S - Sale+OE | $39.90 | -20,000 | 42,963 | -32% | -$798,000 | |||||
| D | 2026-09-08 | ONC | Beone Medicines Ltd. | Wang Xiaodong | Chair, Scientific Advisory Brd | S - Sale+OE | $349.10 | -38,287 | 9,566,326 | 0% | -$13,366,092 | |||||
2026-09-09 | BMY | Bristol Myers Squibb Co | Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | S - Sale | $64.57 | -6,249 | 18,748 | -25% | -$403,498 | ||||||
2026-09-08 | JAZZ | Jazz Pharmaceuticals Plc | Gala Renee D | Pres, CEO | S - Sale | $243.03 | -2,000 | 143,394 | -1% | -$486,060 | ||||||
| D | 2026-09-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $501.84 | -9,500 | 668,728 | -1% | -$4,767,467 | |||||
| D | 2026-09-08 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO, Interim CEO | S - Sale+OE | $22.90 | -17,500 | 181,641 | -9% | -$400,716 | |||||
| M | 2026-09-08 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $2.09 | +15,229 | 2,775,229 | +1% | +$31,896 | |||||
| M | 2026-09-08 | KRRO | Korro Bio, Inc. | Dolan Oliver | SVP, Finance | S - Sale | $13.51 | -7,353 | 16,246 | -31% | -$99,368 | |||||
2026-08-19 | ELTP | Elite Pharmaceuticals Inc /Nv/ | Dash Barry H | Dir | P - Purchase | $0.29 | +30,000 | 3,265,555 | +1% | +$8,610 | ||||||
2026-09-09 | GRCE | Grace Therapeutics, Inc. | Kohli Prashant | CEO | P - Purchase | $2.14 | +100,000 | 121,357 | +468% | +$214,000 | ||||||
2026-09-04 | CYBN | Cybin Inc. | So Eric H. L. | Exec Chair | P - Purchase | $12.09 | +100,000 | 4,418,630 | +2% | +$1,208,900 | ||||||
2026-09-03 | CYBN | Cybin Inc. | Glavine Paul | Chief Growth Officer | P - Purchase | $11.78 | +100,000 | 4,402,193 | +2% | +$1,178,280 | ||||||
| M | 2026-09-04 | ALMS | Alumis Inc. | Akkaraju Srinivas | Dir | P - Purchase | $10.87 | +986,721 | 7,239,362 | +16% | +$10,726,255 | |||||
2026-09-08 | ALMS | Alumis Inc. | Akkaraju Srinivas | Dir | S - Sale | $10.55 | -96,131 | 7,239,362 | -1% | -$1,014,028 | ||||||
| M | 2026-09-04 | BLTE | Belite Bio, Inc | Lin Yu-Hsin | CEO | S - Sale | $190.00 | -100,435 | 70,134 | -59% | -$19,082,549 | |||||
| M | 2026-09-04 | BLTE | Belite Bio, Inc | Chuang Hao-Yuan | CFO | S - Sale | $189.98 | -67,395 | 26,038 | -72% | -$12,803,528 | |||||
| M | 2026-09-04 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.P. | 10% | S - Sale | $7.33 | -259,837 | 3,885,115 | -6% | -$1,905,768 | |||||
| M | 2026-09-04 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $7.33 | -259,837 | 3,885,115 | -6% | -$1,905,768 | |||||
| M | 2026-09-04 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $68.88 | +9,976 | 551,876 | +2% | +$687,160 | |||||
| M | 2026-07-16 | CVSI | Cv Sciences, Inc. | Cheever Charlie E III | 10% | P - Purchase | $0.02 | +5,740,816 | 26,648,711 | +27% | +$114,816 | |||||
2026-09-01 | CYBN | Cybin Inc. | So Eric H. L. | Exec Chair | P - Purchase | $11.81 | +95,000 | 4,318,630 | +2% | +$1,121,475 | ||||||
| DM | 2026-09-04 | HRMY | Harmony Biosciences Holdings, Inc. | Budur Kumar | CHIEF MEDICAL OFFICER | S - Sale+OE | $42.80 | -33,954 | 13,115 | -72% | -$1,453,169 | |||||
| D | 2026-09-08 | ASND | Ascendis Pharma A/S | Bodenhoff Mads | SVP, PAO | S - Sale+OE | $270.19 | -3,000 | 0 | -100% | -$810,570 | |||||
| D | 2026-09-08 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $499.03 | -9,500 | 668,728 | -1% | -$4,740,795 | |||||
2026-09-04 | NAMS | Newamsterdam Pharma Co N.V. | Smither John W | Dir | S - Sale | $25.32 | -1,600 | 8,760 | -15% | -$40,512 | ||||||
2026-09-04 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale | $79.96 | -1,689 | 13,427 | -11% | -$135,052 | ||||||
2026-09-08 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $45.61 | -8,210 | 561,435 | -1% | -$374,498 | ||||||
| D | 2026-09-08 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale+OE | $42.92 | -871 | 59,882 | -1% | -$37,383 | |||||
| D | 2026-09-08 | URGN | Urogen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $42.54 | -1,519 | 53,141 | -3% | -$64,618 | |||||
| D | 2026-09-08 | PHVS | Pharvaris N.V. | Lu Peng | Pres | S - Sale+OE | $40.68 | -15,000 | 65,179 | -19% | -$610,134 | |||||
2026-08-31 | CYBN | Cybin Inc. | Glavine Paul | Chief Growth Officer | P - Purchase | $11.59 | +90,000 | 4,302,193 | +2% | +$1,042,677 | ||||||
| M | 2026-09-03 | ANTX | An2 Therapeutics, Inc. | Readnour Robin Shane | Dir | S - Sale | $6.04 | -16,119 | 634,427 | -2% | -$97,323 | |||||
| D | 2026-08-31 | ATHE | Alterity Therapeutics Ltd | Marks Peter Ashley | Dir | P - Purchase | $0.50 | +47,620 | 191,340 | +33% | +$23,810 | |||||
2026-09-03 | LGND | Ligand Pharmaceuticals Inc | Reardon Andrew | CLO, Secretary | S - Sale | $286.09 | -5,000 | 36,514 | -12% | -$1,430,434 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |